Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HyperSal 6 (HyperSal6) is a sterile, preservative-free hypertonic saline solution containing sodium chloride 6% w/v (1 mmol/mL), formulated for inhalation via a nebuliser. Developed by the Pharmacy Business Unit at the Royal Children's Hospital Melbourne, it acts on the airway surface liquid via osmosis to mobilise and clear respiratory secretions by reducing the thickness and stickiness of mucus in the lungs. It is indicated for conditions requiring improved mucus clearance, including cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease (COPD), and acute lower respiratory tract infections. In clinical trials, it has been evaluated for its feasibility and short-term respiratory benefits in children with severe neurological impairment and acute lower respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride (The Royal Children's Hospital).